Literature DB >> 20831987

The posterior approach in the treatment of popliteal artery aneurysm: feasibility and analysis of outcome.

Francesco Zaraca1, Andrea Ponzoni, Carlo Stringari, Juliane A Ebner, Riccardo Giovannetti, Heinrich Ebner.   

Abstract

BACKGROUND: This review evaluates the results of our 18-year experience with surgical treatment of popliteal artery aneurysms (PAAs), examining the effects of the variables of clinical presentations, surgical technique, graft material, and runoff on operative results in the management of popliteal aneurysms.
METHODS: We reviewed 49 PAAs consecutively repaired in 35 patients. We preferentially use, if possible, the posterior approach for repair of popliteal aneurysms. We repaired aneurysms passing above the Hunter canal using a medial approach to allow for adequate exposure of the proximal neck of the aneurysm. We separately analyzed the results of patients who underwent the posterior approach (group A) and those that underwent the medial approach (group B). Primary, primary assisted, and secondary patency were established using life-tables analysis.
RESULTS: In our experience, the posterior approach was used in 38 repairs (77.6%), followed by graft interposition (group A). PAAs were asymptomatic in 29 (59.2%) of 49 cases. Among 20 symptomatic PAAs, nine (18.4%) caused intermittent claudication, one (2.0%) caused rest pain and trophic wound, and the remaining 10 limbs (20.4%) presented with acute ischemia and limb threat. A total of 11 popliteal aneurysms (22.4%) required repair with a medial approach (group B) because the extension of the aneurysm was proximal to the adductor hiatus. The primary patency rates at 6 and 8 years were 94.3 and 83.8%, respectively, for group A and 100% (p = .43) and 19.1% (p = .001) for group B, the respective assisted primary patency rates were 97.3 and 86.3%, in group A and 100% (p = .43) and 19.1% (p = .001) for group B. The secondary patency rates at 6 months and 8 years were 97.3 and 97.3%, respectively, in group A and 90.9% (p = .34) and 77.9% (p = .05) in group B. Amputation occurred in two (4.1%) of 49 limbs and 30-day postoperative mortality was 2.0% (1/49 patients). There was no statistical difference in amputation rate in symptomatic and asymptomatic limbs, and in group A and B.
CONCLUSION: We believe that the posterior approach is the gold standard surgical therapy to treat PPAs not extending above the Hunter canal. In our experience, the posterior approach was possible in 77.6% of cases. It has excellent patency and prevents further aneurysm expansion by completely interrupting the collateral circulation to the aneurysm sac. In contrast, the posterior approach had a slightly higher tibial nerve injury (p = .43), especially during the learning curve. The preoperative symptoms and the use of venous material for reconstruction affect significantly long-term patency.
Copyright © 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20831987     DOI: 10.1016/j.avsg.2010.04.005

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  4 in total

1.  Bilateral peroneal artery aneurysms.

Authors:  O El Bakbachi; G A Antoniou; R G McWilliams; D R Jones
Journal:  Ann R Coll Surg Engl       Date:  2017-04       Impact factor: 1.891

2.  Long-term results of open repair of popliteal artery aneurysm.

Authors:  M U Wagenhäuser; K B Herma; T A Sagban; P Dueppers; H Schelzig; M Duran
Journal:  Ann Med Surg (Lond)       Date:  2015-02-11

3.  Septic True Aneurysm of the Posterior Tibial Artery Diagnosed after Anterior Arthroscopic Debridement of a Septic Ankle following Infective Endocarditis: A Case Report.

Authors:  Ichiro Tonogai; Hiroki Arase; Yutaka Kawabata; Koichi Sairyo
Journal:  J Orthop Case Rep       Date:  2018 Nov-Dec

4.  True giant posterior tibial artery aneurysm.

Authors:  Alessandro Robaldo; Giacomo Di Iasio; Gabriele Testi; Patrizio Colotto
Journal:  Case Rep Surg       Date:  2012-12-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.